UCL Technology Fund

Oriole Networks is a company focused on enhancing the performance of artificial intelligence systems and optimizing data center operations. By employing advanced optimization techniques and resource utilization strategies, it aims to improve the efficiency of machine learning processes while significantly reducing energy consumption. This innovative approach not only boosts AI performance but also supports industries in adopting sustainable practices, contributing to a more environmentally friendly future.

Gaussion develops a charging technology that uses magneto-electrochemistry to rapidly charge existing battery cells by steering ions, a process designed to reduce cell degradation and extend battery life. It has also created a charging device intended to boost electric vehicle usage by enabling fast charging while preserving battery lifespan and warranty criteria without requiring changes to vehicles or batteries.

Oriole Networks is a company focused on enhancing the performance of artificial intelligence systems and optimizing data center operations. By employing advanced optimization techniques and resource utilization strategies, it aims to improve the efficiency of machine learning processes while significantly reducing energy consumption. This innovative approach not only boosts AI performance but also supports industries in adopting sustainable practices, contributing to a more environmentally friendly future.

Stanhope is a real estate firm based in London, England, specializing in the development of major commercial and mixed-use properties. The company focuses on creating high-quality developments in London and the South East, encompassing a range of projects that include office spaces, retail environments, and integrated mixed-use facilities. By prioritizing innovation and sustainability, Stanhope aims to contribute to the urban landscape while meeting the evolving needs of businesses and communities.

Stanhope AI is a technology company that specializes in teaching robots and machines to make decisions in real-world, untrained situations. It leverages neuroscience, AI, and robotics to create advanced AI designs, enabling machines to adapt and learn from new environments. The company's unique approach involves integrating a model of the brain into machines, enhancing their ability to generalize, be power-efficient, and robust in autonomous systems.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

Phasecraft is a UK-based company founded in 2018 by world-class quantum scientists and engineers. They specialize in developing quantum software for intermediate-scale devices and quantum computers, aiming to accelerate practical applications of quantum computing.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Gaussion develops a charging technology that uses magneto-electrochemistry to rapidly charge existing battery cells by steering ions, a process designed to reduce cell degradation and extend battery life. It has also created a charging device intended to boost electric vehicle usage by enabling fast charging while preserving battery lifespan and warranty criteria without requiring changes to vehicles or batteries.

Hazy is a data technology company that develops an AI-powered platform for synthetic data and automated data anonymization. The platform enables secure, automatic sharing of datasets while identifying and replacing personally identifiable information in evolving datasets, helping data-centric organizations unlock value from data while meeting privacy requirements. Founded in 2017 and based in London, the company aims to enable data to be shared and used more freely, accelerating AI adoption and enhancing business intelligence while maintaining trust.

Intrinsic Semiconductor Technologies develops silicon oxide–based memristive devices with fully air-stable, CMOS-compatible technology. The company specializes in non-volatile and multilevel memory, and its platforms support hardware acceleration for machine learning and neuromorphic computing. Its memristive materials leverage common processing steps to enable integration in standard devices across advanced process nodes, facilitating operation at higher power, frequency, and temperature ranges. In addition to memory functions, the technology underpins low-power, cost-efficient semiconductors, including gallium nitride materials, suitable for diverse applications in data storage, processing, and next-generation computing architectures.

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company’s Delta Zero platform employs deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By integrating continuous improvement methods with AI, Carbon Re aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing. This approach not only targets substantial reductions in carbon emissions but also aims to lower electricity and fuel costs for plants, thereby promoting efficient decarbonization in foundational industries.

Bloomsbury Genetic Therapies is a clinical-stage biotechnology company focused on developing curative treatments for rare neurological and metabolic diseases through gene therapy technologies. The company aims to provide potentially curative therapies for devastating pediatric neurodegenerative conditions, such as infantile neuroaxonal dystrophy, for which there are currently no available treatments. By leveraging clinically proven gene therapy methods, Bloomsbury seeks to enhance therapeutic efficacy and safety while ensuring high manufacturability and efficient development processes. Its pipeline is designed to offer highly differentiated programs that have the potential to be first- or best-in-class solutions for patients in need.

Bramble Energy Ltd. is a London-based company that designs, develops, and manufactures printed circuit board fuel cells (PCBFC), specifically proton exchange membrane fuel cells (PEMFCs). Founded in 2016, the company utilizes innovative PCB technology to create high-performance and cost-effective fuel cell stacks, including variants of 20 W, 500 W, and 5 kW, along with custom-designed options. By leveraging the capabilities of the global high-volume PCB industry, Bramble Energy stands out as the first fuel cell manufacturer with the capacity to produce gigawatts of fuel cell hardware, a feat that has eluded the battery industry for years. The company's products serve various sectors, including stationary, portable, and automotive applications, offering businesses and energy industry players access to efficient solutions that help reduce energy consumption and lower carbon emissions.

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company’s Delta Zero platform employs deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By integrating continuous improvement methods with AI, Carbon Re aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing. This approach not only targets substantial reductions in carbon emissions but also aims to lower electricity and fuel costs for plants, thereby promoting efficient decarbonization in foundational industries.

Apollo Therapeutics is a collaborative venture between leading UK universities and global pharmaceutical companies. It provides committed funding and drug discovery expertise to accelerate novel therapeutics sourced from top British academic research towards clinical trials.

Intrinsic Semiconductor Technologies develops silicon oxide–based memristive devices with fully air-stable, CMOS-compatible technology. The company specializes in non-volatile and multilevel memory, and its platforms support hardware acceleration for machine learning and neuromorphic computing. Its memristive materials leverage common processing steps to enable integration in standard devices across advanced process nodes, facilitating operation at higher power, frequency, and temperature ranges. In addition to memory functions, the technology underpins low-power, cost-efficient semiconductors, including gallium nitride materials, suitable for diverse applications in data storage, processing, and next-generation computing architectures.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.

Bramble Energy Ltd. is a London-based company that designs, develops, and manufactures printed circuit board fuel cells (PCBFC), specifically proton exchange membrane fuel cells (PEMFCs). Founded in 2016, the company utilizes innovative PCB technology to create high-performance and cost-effective fuel cell stacks, including variants of 20 W, 500 W, and 5 kW, along with custom-designed options. By leveraging the capabilities of the global high-volume PCB industry, Bramble Energy stands out as the first fuel cell manufacturer with the capacity to produce gigawatts of fuel cell hardware, a feat that has eluded the battery industry for years. The company's products serve various sectors, including stationary, portable, and automotive applications, offering businesses and energy industry players access to efficient solutions that help reduce energy consumption and lower carbon emissions.

Humanloop is a London-based company that designs and develops an artificial intelligence data labeling and model training platform to scale human-in-the-loop workflows for machine learning and natural language processing. The platform supports data labeling, model training and prompt management, enabling engineers and data scientists to move from idea to deployment with less labeled data while improving prompt development, evaluation and observability. It facilitates training AI models and managing prompts for large language model applications, helping organizations deploy AI capabilities more reliably and efficiently. The company serves clients across tech and consumer sectors, including teams at Gusto, Vanta and Duolingo that use Humanloop to ship reliable AI products.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Astroscreen Ltd is a London-based company that specializes in developing a software as a service (SaaS) platform aimed at detecting astroturfing campaigns and social media manipulation. Incorporated in 2018, Astroscreen utilizes advanced machine learning techniques alongside human intelligence to identify fake accounts, botnets, and spam on social networks. Its platform supports disinformation analysts by verifying social media influence engagement and cleaning data streams, thereby enabling clients to combat marketing fraud and protect against harmful manipulation. By providing accurate insights into social media analytics, Astroscreen helps brands maintain their integrity and defend democracy from deceptive practices online.

Phasecraft is a UK-based company founded in 2018 by world-class quantum scientists and engineers. They specialize in developing quantum software for intermediate-scale devices and quantum computers, aiming to accelerate practical applications of quantum computing.

Scout is developing an innovative web assistance technology that aims to transform how individuals navigate the internet. The company is creating a content-aware browser that not only presents webpages but also comprehends their content and understands user intentions across multiple tasks. This advanced browser will function as a digital assistant, facilitating various online activities such as shopping by finding alternative prices and summarizing reviews, and event planning by checking users' calendars and suggesting routes. By employing techniques such as semantic graphing, natural language processing, and reinforcement learning, Scout's software will enable users to access relevant information seamlessly, eliminating the need for manual searches and enhancing overall online efficiency.

KIT-AR Ltd is a London-based company that specializes in designing and developing integrated industrial augmented reality systems aimed at enhancing manufacturing productivity across various sectors, including automotive, aerospace, and electronics. Founded in 2018, the company focuses on reducing production errors and unplanned downtime caused by human mistakes. KIT-AR offers a suite of products, including KIT-ASSIST, which provides essential assembly and engineering information through a heads-up display; KIT-SMART, a set of intelligent modules that monitor the working environment and worker activity; KIT-BUILD, which enables the management of work instructions; and KIT-INSIGHT, which delivers insights on productivity and efficiency. By leveraging augmented reality and artificial intelligence, KIT-AR empowers shop floor employees to perform tasks correctly and efficiently, ultimately improving overall manufacturing quality.

Hazy is a data technology company that develops an AI-powered platform for synthetic data and automated data anonymization. The platform enables secure, automatic sharing of datasets while identifying and replacing personally identifiable information in evolving datasets, helping data-centric organizations unlock value from data while meeting privacy requirements. Founded in 2017 and based in London, the company aims to enable data to be shared and used more freely, accelerating AI adoption and enhancing business intelligence while maintaining trust.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

Glialign is focused on advancing innovative cell therapies aimed at repairing peripheral nerves, a critical area where existing treatments often fall short, achieving success in less than half of cases. The company has developed regenerative technologies that facilitate surgeries involving living neural tissue. Its primary product is a living nerve growth guide designed for peripheral nerve repair, serving as an effective, off-the-shelf alternative to traditional nerve allografts. This technology eliminates the need for a secondary surgical procedure to harvest nerves from other body parts, thereby streamlining the treatment process. By enabling healthcare providers to guide nerve regeneration, Glialign aims to enhance recovery outcomes for patients suffering from nerve injuries.

Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.

Hazy is a data technology company that develops an AI-powered platform for synthetic data and automated data anonymization. The platform enables secure, automatic sharing of datasets while identifying and replacing personally identifiable information in evolving datasets, helping data-centric organizations unlock value from data while meeting privacy requirements. Founded in 2017 and based in London, the company aims to enable data to be shared and used more freely, accelerating AI adoption and enhancing business intelligence while maintaining trust.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Bloomsbury AI Limited was a London-based company that developed a language processing platform aimed at enabling users to create, utilize, and share text-understanding computer applications. Founded in April 2015 by a team of innovators, the company utilized artificial intelligence to automate expertise and facilitate data analytics through written dialog with computers. This approach allowed users to execute repetitive tasks more efficiently, mimicking the learning process of human apprentices. Bloomsbury AI's technology was designed to read background documents and learn from expert feedback, ultimately creating programs that could perform similar actions. The company, which aimed to streamline the interaction between users and technology, went into liquidation, and at one point was a subsidiary of Facebook, Inc.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.